A Study of ZN-c3 in Patients With Ovarian Cancer

K-Group Beta

Status and phase: Enrolling; Phase 1

Conditions: Solid Tumor; Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer

Treatments: Drug: Pegylated liposomal doxorubicin; Drug: Paclitaxel; Drug: Gemcitabine; Biological: Bevacizumab; Drug: ZN-c3; Drug: Carboplatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT04516447

ZN-c3-002

Details and patient eligibility

About

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.

Enrollment: 140 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed high-grade serous epithelial ovarian carcinoma, fallopian tube, or peritoneal carcinoma.

• Subjects must have received 1 or 2 prior therapeutic regimens/lines of therapy in the advanced or metastatic setting.

• Measurable disease per RECIST version 1.1.

• Adequate hematologic and organ function as defined by the following criteria:

  1. ANC ≥ 1.5 × 10^9/L; excluding measurements obtained within 7 days after daily administration of filgrastim/sargramostim or within 3 weeks after administration of pegfilgrastim.
  2. Platelet count ≥ 100 × 10^9/L; excluding measurements obtained within 3 days after transfusion of platelets or within 3 weeks after administration of platelet growth factors.
  3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × upper limit of normal (ULN). If liver function abnormalities are due to underlying liver metastases, AST and ALT ≤ 5 x ULN.
  4. Total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in the case of Gilbert's disease.
  5. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min.

Exclusion criteria

• Histology of abdominal adenocarcinoma of unknown origin or diagnosis of a borderline ovarian tumor.

• Any of the following treatment interventions within the specified time frame prior to Cycle 1 Day 1:

  1. Major surgery within 28 days.
  2. Radiation therapy within 21 days.
  3. Autologous or allogeneic stem cell transplant within 3 months.

A serious illness or medical condition(s) including, but not limited to, the following:

1. Brain metastases that require immediate treatment or are clinically or radiographically unstable.

2. Myocardial impairment of any cause.

3. Significant gastrointestinal abnormalities.

4. Active or uncontrolled infection.

5. Any evidence of small bowel obstruction as determined by air/fluid levels on computed tomography (CT) scan, recent hospitalization for small bowel obstruction within 3 months prior to Cycle 1 Day 1, or recurrent paracentesis or thoracentesis within 6 weeks prior to Cycle 1 Day 1.

   • Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

140 participants in 5 patient groups

Combination with carboplatin

Experimental group

Description:

combined with azenosertib

Treatment:

Drug: Carboplatin

Drug: ZN-c3

Combination with PLD

Experimental group

Description:

combined with azenosertib

Treatment:

Drug: ZN-c3

Drug: Pegylated liposomal doxorubicin

Combination with paclitaxel

Experimental group

Description:

combined with azenosertib

Treatment:

Drug: ZN-c3

Drug: Paclitaxel

Combination with gemcitabine

Experimental group

Description:

combined with azenosertib

Treatment:

Drug: ZN-c3

Drug: Gemcitabine

Combination with bevacizumab

Experimental group

Description:

combined with azenosertib

Treatment:

Drug: ZN-c3

Biological: Bevacizumab